key: cord-0917216-7gzz4rro authors: Verbruggen, Lisanne C.; Wang, Yuehan; Armenian, Saro H.; Ehrhardt, Matthew J.; van der Pal, Helena J.H.; van Dalen, Elvira C.; van As, Jorrit W.; Bardi, Edit; Baust, Katja; Berger, Claire; Castagnola, Elio; Devine, Katie A.; Gebauer, Judith; Marchak, Jordan Gilleland; Glaser, Adam W.; Groll, Andreas H.; Haeusler, Gabrielle M.; den Hartogh, Jaap; Haupt, Riccardo; Hjorth, Lars; Kato, Miho; Kepák, Tomáš; Koopman, Maria M.W. (Rianne); Langer, Thorsten; Maeda, Miho; Michel, Gisela; Muraca, Monica; Nathan, Paul C.; van den Oever, Selina R.; Pavasovic, Vesna; Sato, Satomi; Schulte, Fiona; Sung, Lillian; Tissing, Wim; Uyttebroeck, Anne; Mulder, Renée L.; Kuehni, Claudia; Skinner, Roderick; Hudson, Melissa M.; Kremer, Leontien C.M. title: Guidance regarding COVID‐19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group date: 2020-09-23 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.28702 sha: 8fd03f786198fe25d4e0a77b3e0d0d70f37e068e doc_id: 917216 cord_uid: 7gzz4rro Childhood, adolescent, and young adult (CAYA) cancer survivors may be at risk for a severe course of COVID‐19. Little is known about the clinical course of COVID‐19 in CAYA cancer survivors, or if additional preventive measures are warranted. We established a working group within the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) to summarize existing evidence and worldwide recommendations regarding evidence about factors/conditions associated with risk for a severe course of COVID‐19 in CAYA cancer survivors, and to develop a consensus statement to provide guidance for healthcare practitioners and CAYA cancer survivors regarding COVID‐19. COVID-19 is an infectious disease caused by a coronavirus (SARS-CoV-2) that emerged in December 2019 in Wuhan, China. 1 The coronavirus has spread rapidly across the globe, and on March 11, 2020, COVID-19 was declared a pandemic by the World Health Organization (WHO). The clinical presentation of COVID-19 ranges from asymptomatic to life-threatening infection requiring hospitalization and critical care. 2 Emerging evidence in the general population indicates that individuals with comorbidities such as cardiopulmonary disease, diabetes, and obesity, or those with advanced age have an increased risk of severe infection and death. [3] [4] [5] [6] Long-term survival of childhood, adolescent, and young adult (CAYA) cancer has improved remarkably due to advances in treatment strategies and supportive care over the past decades. Approximately 80% of children diagnosed with cancer achieve five-year survival, which has resulted in growing numbers of CAYA cancer survivors worldwide. 7 Numerous studies have highlighted that CAYA cancer survivors have a higher risk of chronic health conditions such as subsequent cancers, diabetes mellitus, heart failure, and pulmonary disease, [8] [9] [10] [11] [12] [13] compared with the general population. There is further evidence to suggest that some survivors treated with intensive multimodality approaches (e.g., chemotherapy plus radiation, hematopoietic stem cell transplantation) are at risk for accelerated physiological aging. 14 That said, there is very little known about the incidence of COVID-19 and its clinical course in CAYA cancer survivors, or whether preventive measures are warranted above and beyond those recommended for the general population. The high burden of chronic comorbidities experienced by CAYA cancer survivors raises concern that they may be at increased risk for severe Establishing a statement to guide healthcare providers (HCPs), longterm follow-up clinics, and CAYA cancer survivors about how a history of cancer may affect the courseofCOVID-19 is key to ensuring that survivors take optimal precautions during the current pandemic. With this in mind, we organized an international working group within the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG). 15 We aimed (1) to summarize existing evidence and worldwide recommendations regarding relevant factors and conditions associated with risk for a severe course of COVID-19 and (2) to develop a consensus statement to provide guidance for HCPs and CAYA cancer survivors regarding COVID-19. For this report, CAYA cancer survivors were defined as individuals of any age who were diagnosed with cancer before age 25 years and were at least one year following completion of primary cancer therapy. IGHG is an international collaboration focused on developing widely applicable guidance for the long-term follow-up of CAYA cancer sur- We collected information from the websites of national health institutions and the WHO about recommendations for risk factors and comorbidities associated with higher risk of a severe course of COVID-19 in the general population (Supporting Information File S2). We summarized the risk factors and comorbidities associated with higher risk for a severe course of COVID-19 and identified (dis)concordances. During weekly working group discussion sessions, we evaluated the results of the conclusions of evidence and summary of recommendations on risk groups for the general population, and the relevance of the identified risk factors and comorbidities in the general population for CAYA cancer survivors. Consensus was reached to designate comorbidities and risk factors that were identified in recommendations for the general population by > 70% of the organizations as high risk. We extrapolated these risk factors to CAYA cancer survivors and assumed that same conditions, even when cancer treatment-related (e.g., radiation-related cardiovascular disease), may similarly increase the risk for a severe course of COVID-19 in CAYA cancer survivors. Sixteen conditions have been reported to be associated with a higher risk of a severe course of COVID-19 in the general population (Table 2 and Supporting Information Table S4 ). Among these, older age, endocrine disease, heart disease, lung disease, oncologic disease, immune disorders, or organ transplantation were mentioned by more than 70% of the organizations. The IGHG statement advises that all CAYA cancer survivors adhere to their local and/or national authorities' recommendations for the general population regarding social distancing, frequent handwashing, and wearing masks in specific situations. Based on the recommendations of (inter)national organizations, we concluded that survivors who have the following characteristics or comorbidities may be at increased risk for a severe course of COVID-19: (1) age ≥60 years; (2) cardiovascular disease (e.g., following anthracycline therapy and/or chest radiation); (3) chronic lung disorders (e.g., following chest radiation); (4) diabetes (e.g., following radiation to abdomen or pancreas); and (5) The purpose of this statement is to provide guidance to childhood, adolescent and young adult cancer survivors related to risk and additional preventive measures for Coronavirus Disease 2019 . For this guidance, childhood, adolescent and young adult (CAYA) cancer survivors are defined as individuals of any age who were diagnosed with cancer before age 25 years and are at least one year following completion of primary cancer therapy. Survivors, their caregivers, and health care providers should be mindful that the risk and course of COVID-19 in childhood, adolescent and young adult cancer survivors is not currently known. Thus, the information provided in this guidance is largely extrapolated from medical information from national health services and the World Health Organization (WHO) about COVID-19 in the general population. Based on medical information about COVID-19 in the general population, cancer survivors with the specific health conditions below may have a higher risk for a severe course of COVID-19, especially if they have more than one of these conditions. In addition to these comorbid conditions, a more severe course has been observed in older individuals, especially those 60 years of age or older, which may be because older individuals are more likely to have the chronic health conditions listed in the table. Individuals with conditions and/or use of drugs that affect immune system function may also be at risk for a more severe course of COVID-19 because of their overall higher risk of infection. Examples of cancer treatment-related conditions that may increase a CAYA cancer survivor's risk for a severe course of COVID-19 Heart disease, including but not limited to: • Heart failure requiring medication • History of myocardial infarction (heart attack) Heart disease, including but not limited to: • Cardiomyopathy (heart muscle disease) following anthracycline therapy • Coronary artery disease following chest radiation Chronic lung disorders, including but not limited to: • Chronic obstructive pulmonary disease (COPD) • Severe asthma • Any lung disease causing chronic shortness of breath, difficulty breathing or requiring oxygen therapy Chronic lung disorders, including but not limited to: • Lung fibrosis (scarring) following bleomycin or chest radiation • Chronic lung disease after bone marrow transplant Diabetes following radiation to abdomen or pancreas Conditions and/or use of drugs that affect immune system function, including but not limited to: The COVID-19 pandemic has challenged the delivery of healthcare across the world and will also have consequences for long-term followup services for CAYA cancer survivors. Off therapy clinical evaluations have been limited to increase availability of medical and nursing staff for frontline clinical care at many cancer centers. 24 Consequently, this has resulted in deferral of elective long-term follow-up and primary care appointments for CAYA cancer survivors, who as a group represent a medically vulnerable population. At this point, the long-term impact of these disruptions for CAYA cancer survivors is unclear. To begin to address this concern, a global survey of survivorship clinics is planned to evaluate the impact of COVID-19 on long-term follow-up services and identify ongoing initiatives to facilitate CAYA cancer survivors' access to health resources and services during the current pandemic. It remains to be seen whether recent efforts to expeditiously implement novel healthcare delivery platforms such as telehealth and remote patient monitoring can adequately address healthcare access gaps created by this global pandemic. In conclusion, the IGHG COVID-19 working group provides guidance to CAYA cancer survivors, who in many cases may have comorbid conditions linked to a high risk of a severe course of COVID-19. Our ongoing monitoring of emerging COVID-19 data and recommendations will facilitate modification of guidance relevant to the survivor population. The authors have no conflicts of interest to disclose. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don't. Microbiol Aust Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Cancer statistics Risk of chronic comorbidities in survivors of adolescent and young adult cancer (AYA) The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE) Risk and temporal changes of heart failure among 5-year childhood cancer survivors: a DCOG-LATER study Long-Term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy Increased risk associated with radiation therapy: a report for the childhood cancer survivor study Pulmonary outcomes in survivors of childhood central nervous system malignancies: a report from the Childhood Cancer Survivor Study Premature physiologic aging as a paradigm for understanding increased risk of adverse health across the lifespan of survivors of childhood cancer A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium Balancing the benefits and harms of thyroid cancer surveillance in survivors of childhood, adolescent and young adult cancer: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium Early advice on managing children with cancer during the COVID-19 pandemic and a call for sharing experiences The global COVID-19 Observatory and Resource Center for Childhood Cancer The COVID-19 pandemic: a rapid global response for children with cancer from SIOP Clinical progression of patients with COVID-19 in Shanghai Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan COVID-19 with different severities: a multicenter study of clinical features Prognostic value of NT-proBNP in patients with severe COVID-19 Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China Guidance regarding COVID-19 for survivors of childhood, adolescent and young adult cancer: a statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group We gratefully acknowledge the kind help of Luisa Basset-Salom, Tiago